FBLG_OUT_1 [2025-04-16 14:21:05 -0400] 4197 Bytes | 1116 tokens | Cum: 1116 tkns (13.95% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at FibroBiologics (FBLG) which is at 1.1318 up from 0.9571. So, I pulled together a bunch of data for you to look over real fast. It's still early, 2:21:04 PM on Wed Apr 16, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: FibroBiologics (FBLG)
IPO: 2024-01-31 (1 Year Ago)
Market Cap: $37,727,753
Shares Outstanding: 37,740,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

Here’s a list of headlines for FibroBiologics:

Apr-11-25 08:30AM - FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
Apr-08-25 08:30AM - FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Apr-02-25 08:30AM - FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
Mar-31-25 04:25PM - FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
Mar-27-25 08:30AM - FibroBiologics Announces 2025 Annual Meeting of Stockholders
Mar-21-25 08:30AM - FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
Mar-14-25 08:35AM - Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Mar-12-25 01:12PM - Life Sciences Investor Forum Agenda Announced for March 13th

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-03T02:33:00Z - FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux
B2 - 2025-04-03T02:33:00Z - FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt
B3 - 2025-03-05T00:17:00Z - FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes
B4 - 2025-03-05T00:17:00Z - FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an
B5 - 2024-12-30T19:12:00Z - D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
B6 - 2024-12-23T12:55:00Z - FibroBiologics Announces $25 Million Financing

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for FibroBiologics (FBLG).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

FBLG_OUT_3 [2025-04-16 14:21:06 -0400] 1071 Bytes | 303 tokens | Cum: 1421 tkns (17.76% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/05/3037052/0/fr/FibroBiologics-d%C3%A9pose-une-demande-de-brevet-pour-une-nouvelle-approche-visant-%C3%A0-moduler-l-activit%C3%A9-mitochondriale-%C3%A0-l-aide-de-produits-th%C3%A9rapeutiques-%C3%A0-base-de-fibroblastes.htmlFibroBiologics, a clinical-stage biotechnology company, has filed a patent application for a new method to improve mitochondrial function using fibroblast-based therapies. This approach could lead to new treatment options for chronic diseases caused by mitochondrial dysfunction.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_5 [2025-04-16 14:21:07 -0400] 978 Bytes | 282 tokens | Cum: 1705 tkns (21.31% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-11T12:30:50Z - FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean...
A2 - 2025-04-11T12:56:20Z - FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean | Taiwan News | Apr. 11, 2...
A3 - 2025-04-11T12:36:26Z - FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean...
A4 - 2025-04-08T13:03:19Z - FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthrou...
A5 - 2025-04-08T12:33:40Z - FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and ......

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

FBLG_OUT_7 [2025-04-16 14:21:12 -0400] 1181 Bytes | 340 tokens | Cum: 2047 tkns (25.59% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean**Date: 2025-04-11Source: {'uri': 'eagletribune.com', 'dataType': 'news', 'title': 'Eagle-Tribune'}URL: https://www.eagletribune.com/region/fibrobiologics-to-present-at-the-cell-gene-meeting-on-the-mediterranean/article_7139822d-f1b7-55b6-b605-58b324158fba.htmlHOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_9 [2025-04-16 14:21:15 -0400] 538 Bytes | 136 tokens | Cum: 2185 tkns (27.31% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): ) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond.

Details of the conference and presentations are as follows:

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_11 [2025-04-16 14:21:16 -0400] 1107 Bytes | 297 tokens | Cum: 2484 tkns (31.05% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper ##TABLE_END

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes and othe...

S5 - 2024-12-31 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Second Closing

As previously disclosed, on December 20, 2024 (the Effective Date), FibroBiologics, Inc. (the Company) entered into a Standby Equity Purchase Agrmt (the SEPA) with YA II PN, LTD., a Cayman Islands exempt...

S6 - 2024-12-23 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Standby Equity Purchase Agrmt

On December 20, 2024 (the Effective Date), FibroBiologics, Inc. (the Company) entered into a Standby Equity Purchase Agrmt (the SEPA) with YA II PN, LTD., a Cayman Islands exempt limit...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

FBLG_OUT_13 [2025-04-16 14:21:17 -0400] 1181 Bytes | 232 tokens | Cum: 2718 tkns (33.98% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations ##TABLE_END

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes and other financial information appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the Risk Factors section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_15 [2025-04-16 14:21:18 -0400] 1181 Bytes | 267 tokens | Cum: 2987 tkns (37.34% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6):
Overview

We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Our most advanced product candidates are CYWC628, CYMS101 and CybroCell.

We are in the late pre-clinical stages of developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Our pre-clinical studies focused on utilizing single cell fibroblasts, fibroblast spheroids, and fibroblast-derived materials to treat wounds in diabetic mice. We completed pre-clinical studies investigating (i) multiple administrations of CYWC628 spheroids on a chemically induced chronic wound NONcNZO10

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_17 [2025-04-16 14:21:20 -0400] 1181 Bytes | 280 tokens | Cum: 3269 tkns (40.86% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): /LtJ and BKS.Cg-Dock7m +/+ Leprdb/J mouse model, (ii) dose titration to provide information on the proposed dose range of CYWC628, and (iii) acute and chronic toxicity. The results of our studies have shown statistically significant acceleration in the rate of wound closure in comparison with both a marketed wound care product and control, and improved quality of healed wounds. Based upon our results achieved to date, we are planning to initiate a twelve-week Phase 1/2 clinical trial in Australia for treatment of diabetic foot ulcers in the second half of 2025.

We are developing CYMS101 as a topically administered allogeneic fibroblast single cell, and fibroblast spheroid cell-based therapy to treat MS. After completing animal studies using CYMS101, we received approval from a U.S.-based IRB to conduct clinical investigations in Mexico using the fibroblast cell composition for patients

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_19 [2025-04-16 14:21:22 -0400] 1181 Bytes | 264 tokens | Cum: 3535 tkns (44.19% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): with MS, and completed a Phase 1 study. The study was conducted in five participants. The primary objective of the study was to assess safety, and the secondary objective was to assess efficacy. The primary objective was achieved as we saw no adverse events related to the treatment - no adverse events during intravenous injection of the tolerogenic fibroblasts, no short or long-impact in complete blood count tests during the 16-week monitoring period, and no short or long impact in electrocardiogram results during the 16-week monitoring period. In addition, the study assessed clinical activity using a standard set of neurological assessments routinely used to assess MS. We are currently conducting further research to more fully characterize the mode of action of fibroblasts in oligodendrocyte expansion. We plan to file an IND application for a Phase 1/2 clinical trial relating to MS in

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_21 [2025-04-16 14:21:25 -0400] 1181 Bytes | 264 tokens | Cum: 3801 tkns (47.51% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): the United States as funding allows. We expect to seek a strategic partner to collaborate with us on the development of CYMS101 either before initiating the Phase 1/2 study, or after its completion, if successful, and prior to commencing a potential Phase 3 clinical trial.

CybroCell is an investigational allogeneic fibroblast cell-based therapy in development for degenerative disc disease and is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). We have completed two animal studies in rabbit models. The results from the studies were positive and supported our IND application to run a first in human trial. We received IND clearance from the FDA in 2018, conditional upon approval of our master cell bank, to evaluate this candidate in a planned clinical trial. A timeline for the trial will be determined in conn

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_23 [2025-04-16 14:21:26 -0400] 790 Bytes | 186 tokens | Cum: 3989 tkns (49.86% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): ection with discussions with the FDA.

CYPS317 is our allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. We have completed an early phase pre-clinical project utilizing a psoriasis mouse model to assess the potential use of intravenous administration of fibroblast spheroids for the treatment of psoriasis. We are in the process of continuing our potentially IND-enabling animal model studies, which include carrying out a do...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

FBLG_OUT_25 [2025-04-16 14:21:32 -0400] 6273 Bytes | 1736 tokens | Cum: 5727 tkns (71.59% of 8k)
==========================================================================

This is our set of metrics for FibroBiologics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 349,013 | Perf Month: 13.27% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 302.43K | Perf Quarter: -45.05% | Short Float: 7.69% | ROE: -559.73% |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 1.60 | Index: RUT | Short Ratio: 7.45 | ROI: -300.11% |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 57.26 | Market Cap: 41.89M | Short Interest: 2.25M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.11 | Shs Outstand: 35.09M | Beta: -0.35 | EPS Surprise: -5.56% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: 16.28% | Shs Float: 29.27M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -1.81% | Inst Own: 16.00% | Sales past 5Y: 0.00% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -53.84% | Insider Own: 22.43% | Employees: 13 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: 30.59% | Insider Trans: 0.00% | Debt/Eq: 3.86 | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading by FibroBiologics officers or majority shareholders (if available).

Inside Trans: FibroBiologics, Inc. (FBLG) by Khoja Hamid (CHIEF SCIENTIFIC OFFICER) on 2025-03-26
- Stock Option (Right to Buy): 189000 shares at $0 (D)

Inside Trans: FibroBiologics, Inc. (FBLG) by GARCIA RUBEN A (General Counsel) on 2025-03-26
- Stock Option (Right to Buy): 189000 shares at $0 (D)

Inside Trans: FibroBiologics, Inc. (FBLG) by O'HEERON PETE (CHIEF EXECUTIVE OFFICER) on 2025-03-26
- Stock Option (Right to Buy): 453000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -500000, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.1318
Average Volume: 173256.48
30-Day High: 1.1318
30-Day Low: 0.8128

[Detailed Financials: Q3 2024]
- Total Assets: $10,469,000.0
- Total Liabilities: $7,732,000.0
- Total Equity: $2,737,000.0
- Current Assets: $8,198,000.0
- Current Liabilities: $6,677,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.01

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $1,854,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $8,912,000.0
- Total Liabilities: $11,299,000.0
- Total Equity: $-2,387,000.0
- Current Assets: $6,509,000.0
- Current Liabilities: $10,132,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.03

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-2,185,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of FibroBiologics (FBLG).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about FibroBiologics.

2) MARKET_SCORE[]
This conversation was initiated because FBLG is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for FBLG.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, FBLG could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect FBLG to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of FibroBiologics.

11) ETHICAL_RATING[]
Rate FibroBiologics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of FibroBiologics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

FBLG_IN_27 [2025-04-16 14:21:33 -0400] 126 Bytes | 29 tokens | Cum: 5958 tkns (74.48% of 8k)
==========================================================================

====================================
[2025-04-16 14:21:33] # Analysis Completed
Elapsed Time: 28.37 seconds